Citations

Clear

118 citation(s) found for "Singer, Wolfgang".

Sex and Gender Differences Influence Urinary Symptoms and Management in Multiple System Atrophy (P8-9.001)
Schipani, Elke , Sandroni, Paola , Benarroch, Eduardo E. , Bower, James , Low, Phillip A. , Hooshmand, Sara, Badihian, Negin , Bower, James, Singer, Wolfgang , Coon, Elizabeth A.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000201904 Get It

The Effects of Deep Brain Stimulation in Patients with Multiple System Atrophy
Jackson, Lauren , Klassen, Bryan T. , Hassan, Anhar , Low, Phillip A. , Badihian, Negin , Jackson, Lauren M, Singer, Wolfgang , Coon, Elizabeth A.

Mayo Clinic

Journal of Parkinson's Disease | November 22, 2022 | Volume: 12 | Issue: 8 | Pages: 2595-2600

10.3233/jpd-223504 | PMID 36442207 Get It

The course of patients with multiple system atrophy (MSA) who undergo deep brain stimulation (DBS) is unclear. In a retrospective review of 1,496 patients with MSA evaluated at our institutions from 1998–2021, 12 patients underwent DBS; 9 had a diagnosis of Parkinson’s disease at the time of surgery. Nine patients reported initial improvement in at least one symptom and 7 experienced overall worsening following DBS. All patients had at least one red flag sign or symptom suggesting atypical parkinsonism prior to surgery. Considering overall poor outcomes of DBS in MSA, we recommend careful consideration of red flags in patient selection.
Standardized Autonomic Testing in Patients With Probable Radiation-Induced Afferent Baroreflex Failure
Lamotte, Guillaume , Coon, Elizabeth A., Suarez, Mariana D., Sandroni, Paola, Benarroch, Eduardo, Cutsforth‐Gregory, Jeremy K. , Mauermann, Michelle L., Berini, Sarah E., Shouman, Kamal, Sletten, David, Goodman, Brent P., Low, Phillip A., Mauermann, Michelle L. , Singer, Wolfgang , Mauermann, Michelle L , Lamotte, Guillaume , Coon, Elizabeth A., Suarez, Mariana D., Sandroni, Paola, Benarroch, Eduardo, Cutsforth-Gregory, Jeremy K , Berini, Sarah E., Shouman, Kamal, Sletten, David, Goodman, Brent P., Low, Phillip A.

Mayo Clinic

Hypertension | November 5, 2021 | Volume: 79 | Issue: 1 | Pages: 50-56

10.1161/hypertensionaha.121.17805 | PMID 34739766 Get It

Injury of the afferent limb of the baroreflex from neck radiation causes radiation-induced afferent baroreflex failure (R-ABF). Identification and management of R-ABF is challenging. We aimed to investigate the pattern of autonomic dysfunction on standardized autonomic testing in patients with probable R-ABF. We retrospectively analyzed all autonomic reflex screens performed at Mayo Clinic in Rochester, MN, between 2000 and 2020 in patients with probable R-ABF. Additional tests reviewed included ambulatory blood pressure monitoring, plasma norepinephrine, and thermoregulatory sweat test. We identified 90 patients with probable R-ABF. Median total composite autonomic severity score (range, 0–10) was 7 (interquartile range, 6–7). Cardiovascular adrenergic impairment was seen in 85 patients (94.4%), increased blood pressure recovery time after Valsalva maneuver in 71 patients (78.9%; median 17.4 seconds), and orthostatic hypotension in 68 patients (75.6%). Cardiovagal impairment was demonstrated by abnormal heart rate responses to deep breathing (79.5%), Valsalva ratio (87.2%), and vagal baroreflex sensitivity (57.9%). Plasma norepinephrine was elevated and rose appropriately upon standing (722–1207 pg/mL). Ambulatory blood pressure monitoring revealed hypertension, postural hypotension, hypertensive surges, tachycardia, and absence of nocturnal dipping. Blood pressure lability correlated with impaired vagal baroreflex function. Postganglionic sympathetic sudomotor function was normal in most cases; the most frequent thermoregulatory sweat test finding was focal neck anhidrosis (78.9%). Standardized autonomic testing in R-ABF demonstrates cardiovascular adrenergic impairment with orthostatic hypotension, blood pressure lability, and elevated plasma norepinephrine. Cardiovagal impairment is common, while sudomotor deficits are limited to direct radiation effects.
Alpha‐Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure
Singer, Wolfgang , Schmeichel, Ann M., Schmelzer, James D., Sletten, David M., Gehrking, Tonette L., Gehrking, Jade A., Olson, Anita D., Suarez, Mariana, Misra, Pinaki , Low, Phillip A. , Suarez, Mariana D., Misra, Pinaki P, Singer, Wolfgang , Misra, Pinaki , Shahnawaz, Mohammad , Soto, Claudio A.

Mayo Clinic

Annals of Neurology | April 22, 2021 | Volume: 89 | Issue: 6 | Pages: 1212-1220

10.1002/ana.26089 | PMID 33881777 Get It

Objective To explore the role of alpha‐synuclein (αSyn) oligomers and neurofilament light chain (NfL) in cerebrospinal fluid (CSF) of patients with pure autonomic failure (PAF) as markers of future phenoconversion to multiple system atrophy (MSA). Methods Well‐characterized patients with PAF (n = 32) were enrolled between June 2016 and February 2019 at Mayo Clinic Rochester and followed prospectively with annual visits to determine future phenoconversion to MSA, Parkinson's disease (PD), or dementia with Lewy bodies (DLB). ELISA was utilized to measure NfL and protein misfolding cyclic amplification (PMCA) to detect αSyn oligomers in CSF collected at baseline. Results Patients were followed for a median of 3.9 years. Five patients converted to MSA, 2 to PD, and 2 to DLB. NfL at baseline was elevated only in patients who later developed MSA, perfectly separating those from future PD and DLB converters as well as non‐converters. ASyn‐PMCA was positive in all but two cases (94%). The PMCA reaction was markedly different in five samples with maximum fluorescence and reaction kinetics previously described in MSA patients; all of these patients later developed MSA. Interpretation αSyn‐PMCA is almost invariably positive in the CSF of patients with PAF establishing this condition as α‐synucleinopathy. Both NfL and the magnitude and reaction kinetics of αSyn PMCA faithfully predict which PAF patients will eventually phenoconvert to MSA. This finding has important implications not only for prognostication, but also for future trials of disease modifying therapies, allowing for differentiation of MSA from Lewy body synucleinopathies before motor symptoms develop. ANN NEUROL 2021;89:1212–1220
Loss of putative GABAergic neurons in the ventrolateral medulla in multiple system atrophy
Schmeichel, Ann M., Parisi, Joseph E., Singer, Wolfgang , Low, Phillip A. , Benarroch, Eduardo E. , Singer, Wolfgang , Coon, Elizabeth A.

Mayo Clinic

Sleep | March 23, 2021 | Volume: 44 | Issue: 9 | Pages: No page available

10.1093/sleep/zsab074 | PMID 33755181 Get It

Abstract Study Objectives Multiple system atrophy (MSA) is associated with disturbances in cardiovascular, sleep and respiratory control. The lateral paragigantocellular nucleus (LPGi) in the ventrolateral medulla (VLM) contains GABAergic neurons that participate in control of rapid eye movement (REM) sleep and cardiovagal responses. We sought to determine whether there was loss of putative GABAergic neurons in the LPGi and adjacent regions in MSA. Methods Sections of the medulla were processed for GAD65/67 immunoreactivity in eight subjects with clinical and neuropathological diagnosis of MSA and in six control subjects. These putative GABAergic LPGi neurons were mapped based on their relationship to adjacent monoaminergic VLM groups. Results There were markedly decreased numbers of GAD-immunoreactive neurons in the LPGi and adjacent VLM regions in MSA. Conclusions There is loss of GABAergic neurons in the VLM, including the LPGi in patients with MSA. Whereas these findings provide a possible mechanistic substrate, given the few cases included, further studies are necessary to determine whether they contribute to REM sleep-related cardiovagal and possibly respiratory dysregulation in MSA.
Alpha‐Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies
Singer, Wolfgang , Schmeichel, Ann M., Schmelzer, James D., Sletten, David M., Gehrking, Tonette L., Gehrking, Jade A., Olson, Anita D., Savica, Rodolfo , Suarez, Mariana, Low, Phillip A. , Suarez, Mariana D., Low, Phillip A , Singer, Wolfgang , Shahnawaz, Mohammad , Boeve, Bradley F. , Soto, Claudio A.

Mayo Clinic

Annals of Neurology | June 18, 2020 | Volume: 88 | Issue: 3 | Pages: 503-512

10.1002/ana.25824 | PMID 32557811 Get It

ObjectiveTo explore the role of alpha‐synuclein (αSyn) oligomers and neurofilament light chain (NFL) in cerebrospinal fluid (CSF) as markers of early multiple system atrophy (MSA) and to contrast findings with Lewy body synucleinopathies.MethodsIn a discovery cohort of well‐characterized early MSA patients (n = 24) and matched healthy controls (CON, n = 14), we utilized enzyme‐linked immunosorbent assay to measure NFL and protein misfolding cyclic amplification (PMCA) to detect αSyn oligomers in CSF. We confirmed findings in a separate prospectively enrolled cohort of patients with early MSA (n = 38), Parkinson disease (PD, n = 16), and dementia with Lewy bodies (DLB, n = 13), and CON subjects (n = 15).ResultsIn the discovery cohort, NFL was markedly elevated in MSA patients, with perfect separation from CON. αSyn‐PMCA was nonreactive in all CON, whereas all MSA samples were positive. In the confirmatory cohort, NFL again perfectly separated MSA from CON, and was significantly lower in PD and DLB compared to MSA. PMCA was again nonreactive in all CON, and positive in all but 2 MSA cases. All PD and all but 2 DLB samples were also positive for αSyn aggregates but with markedly different reaction kinetics from MSA; aggregation occurred later, but maximum fluorescence was higher, allowing for perfect separation of reactive samples between MSA and Lewy body synucleinopathies.InterpretationNFL and αSyn oligomers in CSF faithfully differentiate early MSA not only from CON but also from Lewy body synucleinopathies. The findings support the role of these markers as diagnostic biomarkers, and have important implications for understanding pathophysiologic mechanisms underlying the synucleinopathies. ANN NEUROL 2020;88:503–512